[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
1. Costa NM, Rodrigues H, Pereira H, Pardal F, Matos E: Secretory breast carcinoma--case report and review of the medical literature. Breast; 2004 Aug;13(4):353-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretory breast carcinoma--case report and review of the medical literature.
  • Secretory breast carcinoma (SBC) is a rare type of invasive breast cancer.
  • We present the case of an 18-year-old woman with a SBC treated by mastectomy (Madden) and axillary node dissection (stage pT3N1M0) followed by chemotherapy (FEC regimen) and radiotherapy.
  • The authors review the literature and summarize relevant findings concerning definition, pathology, clinical picture, treatment, and follow-up.
  • [MeSH-major] Breast Neoplasms / secretion. Breast Neoplasms / surgery. Carcinoma / secretion. Carcinoma / surgery. Mastectomy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Axilla. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymph Node Excision. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Secretory breast carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15325674.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; FEC protocol
  •  go-up   go-down


2. Jensen SB, Mouridsen HT, Reibel J, Brünner N, Nauntofte B: Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. Oral Oncol; 2008 Feb;44(2):162-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction.
  • It is an open question if chemotherapy (CT) per se imposes adverse effects on salivary gland function.
  • The aim of the present study was to investigate effects of CT on salivary function in breast cancer patients during and after adjuvant CT.
  • Forty-five breast cancer patients, eligible for adjuvant CT with CEF or CMF (cyclophosphamide, epirubicin or methotrexate, 5-fluorouracil) were followed before, during, six months and one year after CT.
  • Findings were compared to those in a control group of 31 breast cancer patients not receiving CT.
  • Xerostomia scores rose during CT and stayed elevated one year after treatment.
  • UWS and SWS total protein output and UWS secretory IgA output decreased in response to CT.
  • These adverse drug reactions are temporary, as salivary findings generally returned to baseline values within one year following treatment.
  • [MeSH-major] Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Salivary Glands / drug effects. Xerostomia / chemically induced
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Chemotherapy, Adjuvant / adverse effects. Chi-Square Distribution. Electrolytes / analysis. Female. Humans. Hydrogen-Ion Concentration. Immunoglobulin A, Secretory / analysis. Middle Aged. Saliva / chemistry. Salivary Proteins and Peptides / analysis. Salivation / drug effects. Secretory Rate


3. Polyzos PT, Arvanitis LD, Charchanti A, Galani V, Havaki S, Kallioras VA, Nakou M, Faros EG, Marinos E, Sgantzos MN, Kittas C: Decidualized and pre-decidualized normal endometrial stromal cells produce more O-linked N-acetylglucosamine containing epitope H than non-decidualized normal endometrial stromal cells. Histol Histopathol; 2006 11;21(11):1193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, in extracts of cultured MCF-7 breast carcinoma cell line cells it stains cytokeratin 8 and five polypeptides originating from Triton X-100-soluble (Mr x10(-3) of 232, 67 and 37) and from the Triton X-100-insoluble (Mr x10(-3) of 51 and 50) fractions, respectively.
  • In our previous studies we used the mAbH to investigate by immunostaining the expression of the epitope H in normal human brains, human brains with a variety of lesions, astrocytic tumors, infiltrating ductal breast carcinomas, fibroadenomas, and mitochondria-rich normal, metaplastic and neoplastic cells.
  • In order to gain further insight into the expression patterns of the epitope H in human tissues we used the mAbH to investigate the immunohistochemical expression of the epitope H in normal human endometrium, including 30 cases of proliferative endometrium, 30 cases of early secretory endometrium, 30 cases of mid secretory endometrium, 30 cases of late secretory endometrium and 30 cases of decidual tissues.
  • 1) The decidual stromal cells presented in all cases high cytoplasmic expression of the epitope H;.
  • 2) The pre-decidual stromal cells presented in all cases of late secretory endometrium significant cytoplasmic expression of the epitope H ranging from moderate to high expression;.
  • 3) The non pre-decidual stromal cells of the functional endometrial layer presented in all cases insignificant cytoplasmic expression of the epitope H ranging from null to low expression;.

  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16874662.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Epitopes; 0 / Peptides; 4G7DS2Q64Y / Progesterone; 68238-35-7 / Keratins; 9002-93-1 / Octoxynol; V956696549 / Acetylglucosamine
  •  go-up   go-down


Advertisement
4. Rivera-Hueto F, Hevia-Vázquez A, Utrilla-Alcolea JC, Galera-Davidson H: Long-term prognosis of teenagers with breast cancer. Int J Surg Pathol; 2002 Oct;10(4):273-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term prognosis of teenagers with breast cancer.
  • We report 4 new cases of breast carcinoma in teenage girls diagnosed by use of histochemical and immunohistochemical methods.
  • These cases of breast carcinoma in women under 20 years of age were found in the files of our department in the last 24 years (1976-2000).
  • The patients had operable breast carcinomas corresponding to various histologic types (1 invasive ductal carcinoma associated with fibroadenoma, 2 secretory carcinomas, and 1 invasive lobular-type carcinoma).
  • Only 1 patient received adjuvant chemotherapy (case 4).
  • The correlations with prognosis-related risk factors (stage, age, previous benign lesions, family history, histologic types, hormonal receptors, and pregnancy) were examined.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Child. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Mastectomy. Pregnancy. Pregnancy Complications, Neoplastic. Spain / epidemiology. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12490977.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Szántó J, András C, Tsakiris J, Gomba S, Szentirmay Z, Bánlaki S, Szilágyi I, Kiss C, Antall P, Horváth A, Lengyel L, Castiglione-Gertsch M: Secretory breast cancer in a 7.5-year old boy. Breast; 2004 Oct;13(5):439-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretory breast cancer in a 7.5-year old boy.
  • Breast cancer is extremely rare in children, and consequently no consensus has been reached on the optimal treatment modalities.
  • The medical history and treatment plan for a 7.5-year old male breast cancer patient is described.
  • As no malignant cells were detected in the sentinel node, and no BRCA1-2 mutations were detected, no further radio- or chemotherapy was performed.
  • Further treatment will be given if this becomes necessary with the development of metastases.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Carcinoma / pathology


6. Vieni S, Cabibi D, Cipolla C, Fricano S, Graceffa G, Latteri MA: Secretory breast carcinoma with metastatic sentinel lymph node. World J Surg Oncol; 2006;4:88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretory breast carcinoma with metastatic sentinel lymph node.
  • BACKGROUND: Secretory mammary carcinoma is a rare breast neoplasia originally described in children but sometimes also found in adults.
  • It presents a more favourable outcome than more common histological types of breast carcinoma; published literature in fact reports only a few cases with axillary lymph node metastases and only four cases with distant metastases.
  • CLINICAL PRESENTATION: In this paper we report a rare case of secretory breast carcinoma with axillary lymph node metastases in a 33-year-old woman.
  • To our knowledge, this is the first case of secretory carcinoma involving biopsy of the sentinel lymph node and investigation of the e-cadherin expression.
  • We found positivity for e-cadherin, which would support the hypothesis that this type of tumour is a variant of the infiltrating ductal carcinoma.
  • CONCLUSION: After a careful analysis of reported data, we have come to the conclusion that the treatment of choice for patients with secretory breast carcinoma should be conservative surgery with sentinel lymph node biopsy, followed by accurate follow-up.
  • Although several cases of secretory carcinoma have been treated with adjuvant chemotherapy, there are still no reliable data regarding the real value of such a choice.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1994 May-Jun;38(3):446-50 [8191840.001]
  • [Cites] Cancer. 1980 May 1;45(9):2404-13 [6445777.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):715-21 [8391221.001]
  • [Cites] Lancet. 1997 Jun 28;349(9069):1864-7 [9217757.001]
  • [Cites] Acta Cytol. 1998 Jul-Aug;42(4):1032-6 [9684599.001]
  • [Cites] J Clin Pathol. 1998 Jul;51(7):545-7 [9797736.001]
  • [Cites] Pathol Int. 1998 Dec;48(12):994-7 [9952346.001]
  • [Cites] Clin Exp Pathol. 1999;47(2):88-91 [10398580.001]
  • [Cites] Pathology. 1999 May;31(2):166-8 [10399175.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1435-40 [10667421.001]
  • [Cites] J Pediatr Surg. 2000 May;35(5):765-7 [10813345.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1343-7 [11106125.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):663-7 [12167580.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):646-52 [15073596.001]
  • [Cites] World J Surg Oncol. 2004;2:17 [15175103.001]
  • [Cites] Breast. 2004 Aug;13(4):353-5 [15325674.001]
  • [Cites] Breast. 2004 Oct;13(5):439-42 [15454204.001]
  • [Cites] Arch Pathol Lab Med. 1991 Feb;115(2):141-4 [1992979.001]
  • [Cites] J Surg Oncol. 1990 Aug;44(4):238-44 [2200927.001]
  • [Cites] Histopathology. 1989 Jan;14(1):25-36 [2925177.001]
  • [Cites] J Pediatr Surg. 1985 Aug;20(4):368-71 [4045662.001]
  • [Cites] Am J Pathol. 1993 Dec;143(6):1731-42 [8256859.001]
  • [Cites] Mod Pathol. 1994 May;7(4):475-9 [8066076.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):987-93 [7682767.001]
  • (PMID = 17150092.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1764883
  •  go-up   go-down


7. Herz H, Cooke B, Goldstein D: Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: case report and review of the literature. Ann Oncol; 2000 Oct;11(10):1343-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: case report and review of the literature.
  • Secretory carcinoma of the breast is a rare and indolent tumour originally described in children but occurring equally in the adult population.
  • The principal management problems following primary surgical treatment are local recurrence and axillary lymph node metastases.
  • We present the case of a 27-year-old woman with pulmonary metastases from a secretory breast cancer treated by mastectomy and axillary lymph node dissection 12 years previously.
  • There was no response to chemotherapy; however, the patient remained alive and active two years from presentation with metastatic disease and one year from cessation of all cytotoxic chemotherapy.
  • To our knowledge, this is only the fourth reported case of distant metastases from secretory breast cancer and the second reported case in which current active chemotherapy has been used.
  • In the absence of any proven effective chemotherapy we believe that symptom control becomes the focus of management and offers patients with metastatic secretory breast cancer the greatest chance of a functional and good quality existence.


8. Ozguroglu M, Tascilar K, Ilvan S, Soybir G, Celik V: Secretory carcinoma of the breast. Case report and review of the literature. Oncology; 2005;68(2-3):263-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretory carcinoma of the breast. Case report and review of the literature.
  • We report an elderly case of an indolent breast tumor in a 66-year-old woman.
  • The patient presented with a locally advanced mass in the right breast that was present for 13 years, accompanied by bleeding and ulceration since the last 5 years.
  • She was found to have secretory carcinoma with a tumor size of 8 x 4 x 4 cm in diameter.
  • The secretory material stained positive with lactalbumin, as well as showed positivity with PAS.
  • The patient received six cycles of adjuvant chemotherapy followed by chest wall irradiation.
  • She is disease free with a follow-up period of 24 months.
  • Preoperative chemotherapy should be primarily replaced by curative surgery in such indolent cancers, despite locally advanced disease.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Hemorrhage / etiology. Humans. Lymphatic Metastasis. Radiotherapy, Adjuvant. Ulcer / etiology

  • Genetic Alliance. consumer health - Secretory breast carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16015043.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 54
  •  go-up   go-down


9. Arce C, Cortes-Padilla D, Huntsman DG, Miller MA, Dueñnas-Gonzalez A, Alvarado A, Pérez V, Gallardo-Rincón D, Lara-Medina F: Secretory carcinoma of the breast containing the ETV6-NTRK3 fusion gene in a male: case report and review of the literature. World J Surg Oncol; 2005;3:35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretory carcinoma of the breast containing the ETV6-NTRK3 fusion gene in a male: case report and review of the literature.
  • SUMMARY: Secretory carcinoma (SC) of the breast is a rare and indolent tumor.
  • CASE PRESENTATION: A 52-year-old male was diagnosed with secretory breast carcinoma and underwent a modified radical mastectomy.
  • At 18 months the tumor recurred at the chest wall and the patient developed lung metastases.
  • He was treated concurrently with radiation and chemotherapy without response.
  • There are insufficient data to support the use of adjuvant radiation or chemotherapy.
  • Its association with the ETV6-NTRK3 fusion gene gives some clues for the better understanding of this neoplasm and eventually, the development of specific therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1994 May;7(4):475-9 [8066076.001]
  • [Cites] Acta Cytol. 1994 May-Jun;38(3):446-50 [8191840.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):715-21 [8391221.001]
  • [Cites] Acta Cytol. 1998 Jul-Aug;42(4):1032-6 [9684599.001]
  • [Cites] J Clin Pathol. 1998 Jul;51(7):545-7 [9797736.001]
  • [Cites] Pathol Int. 1998 Dec;48(12):994-7 [9952346.001]
  • [Cites] Eur J Surg Oncol. 1999 Feb;25(1):98-9 [10188866.001]
  • [Cites] Clin Exp Pathol. 1999;47(2):88-91 [10398580.001]
  • [Cites] Pathology. 1999 May;31(2):166-8 [10399175.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1343-7 [11106125.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):663-7 [12167580.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):347-8 [12450787.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):367-76 [12450792.001]
  • [Cites] Med Pediatr Oncol. 2003 May;40(5):288-92 [12652616.001]
  • [Cites] Adv Anat Pathol. 2003 Sep;10(5):243-60 [12973047.001]
  • [Cites] Cell. 2003 Nov 26;115(5):523-35 [14651845.001]
  • [Cites] Hum Pathol. 2003 Dec;34(12):1299-305 [14691916.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jun;40(2):152-7 [15101049.001]
  • [Cites] Med Pediatr Oncol. 1992;20(4):341-4 [1608359.001]
  • [Cites] World J Surg Oncol. 2004;2:17 [15175103.001]
  • [Cites] Breast. 2005 Feb;14(1):71-4 [15695086.001]
  • [Cites] Arch Pathol Lab Med. 1991 Feb;115(2):141-4 [1992979.001]
  • [Cites] J Surg Oncol. 1990 Aug;44(4):238-44 [2200927.001]
  • [Cites] Diagn Cytopathol. 1987 Sep;3(3):234-7 [2822366.001]
  • [Cites] Histopathology. 1989 Jan;14(1):25-36 [2925177.001]
  • [Cites] Am J Surg Pathol. 1988 Feb;12(2):150-4 [3341512.001]
  • [Cites] J Pediatr Surg. 1987 Jul;22(7):637-9 [3612460.001]
  • [Cites] J Pediatr Surg. 1985 Aug;20(4):368-71 [4045662.001]
  • [Cites] Cancer. 1973 Mar;31(3):726-8 [4693600.001]
  • [Cites] Can Med Assoc J. 1969 Jul 26;101(2):100-2 [5794134.001]
  • [Cites] Pathology. 1977 Oct;9(4):341-6 [593733.001]
  • [Cites] Cancer. 1983 Jun 15;51(12):2245-54 [6189573.001]
  • [Cites] Cancer. 1980 May 1;45(9):2404-13 [6445777.001]
  • [Cites] Hum Pathol. 1981 Nov;12(11):1044-6 [7319493.001]
  • [Cites] Am J Surg Pathol. 1980 Oct;4(5):465-70 [7435774.001]
  • (PMID = 15963235.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1184104
  •  go-up   go-down


10. Constantinidou A, Jones RL, Reis-Filho JS: Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther; 2010 Aug;10(8):1197-213
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond triple-negative breast cancer: the need to define new subtypes.
  • Advances in the systemic treatment of early breast cancer have led to significant improvements in survival for patients with hormone receptor- and/or HER2-positive disease.
  • These tumors, however, encompass a wide range of subtypes with varying prognosis, including a number of special types with a good prognosis (e.g., adenoid cystic carcinomas and secretory carcinoma).
  • The similarities between sporadic triple-negative cancers and tumors arising in BRCA1 mutation carriers and the fact that the majority of BRCA1 tumors display a triple-negative phenotype have led to studies demonstrating a potential loss of BRCA1 function in triple-negative cancers and offered potential therapeutic avenues for patients with these cancers.
  • However, it should be noted that triple-negative breast cancers comprise a heterogeneous group of tumors.
  • Understanding the molecular underpinning of distinct subgroups of these cancers is crucial for the identification of novel therapeutic targets and individualization of treatment for patients with triple-negative disease.
  • [MeSH-major] Breast Neoplasms / classification. Breast Neoplasms / metabolism. Receptor, ErbB-2 / classification. Receptor, ErbB-2 / deficiency. Receptors, Estrogen / classification. Receptors, Estrogen / deficiency. Receptors, Progesterone / classification. Receptors, Progesterone / deficiency
  • [MeSH-minor] Animals. Antineoplastic Agents / administration & dosage. Drug Delivery Systems / trends. Female. Gene Expression Profiling / trends. Humans


11. Miettinen M: From morphological to molecular diagnosis of soft tissue tumors. Adv Exp Med Biol; 2006;587:99-113
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From morphological to molecular diagnosis of soft tissue tumors.
  • Cytogenetic discoveries of balanced translocations in soft tissue tumors have opened the way to molecular genetic definition of these translocations as gene fusions from the late 1980s.
  • Many sarcomas are known to have such fusions, and the demonstration of the fusion transcripts in tumor tissue is of great value in specific diagnosis of synovial sarcoma (SYT-SSX), Ewing sarcoma (EWS-Fli1), clear cell sarcoma (EWS-ATF1), myxoid liposarcoma (FUS-CHOP), and other sarcomas.
  • Demonstration of SYT-SSX and EWS-ATF1 fusion assists in the diagnosis of synovial and clear cell sarcomas in unusual locations, such as the gastrointestinal tract, where these tumors occur with low frequency.
  • In two exceptional instances, the same translocation and gene fusion occurs in two unrelated diseases: ETV6-NTRK fusion in infantile fibrosarcoma and secretory carcinoma of the breast, and ALK-TPM3 fusion in inflammatory myofibroblastic tumor and large cell anaplastic lymphoma.
  • Activating mutations in two related receptor tyrosine kinases (RTKs), KIT, and platelet-derived growth factor receptor alpha (PDGFRA) is central to the pathogenesis of gastrointestinal stromal tumors (GISTs), and countering the mutational activation by specific tyrosine kinase inhibitors, such as Imatinib mesylate, is now standard treatment for metastatic GISTs.
  • Mutation type influences therapy responsiveness, but fortunately very few GISTs carry primarily Imatinib-resistant mutations.
  • Secondary drug resistance acquired during Imatinib treatment based on new, Imatinib-resistant mutations is a major problem limiting treatment success.
  • Schwannoma types may differ in their pathogenesis: gastrointestinal schwannomas lack NF2 changes suggesting a different pathogenesis.
  • [MeSH-major] Genetic Testing. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163160.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


12. Wheeler DT, Bristow RE, Kurman RJ: Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol; 2007 Jul;31(7):988-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
  • The treatment of complex atypical hyperplasia (CAH) and well-differentiated endometrioid carcinoma (WDC) by progestin therapy has been shown to be a safe alternative to hysterectomy.
  • Accurate assessment for regressive changes induced by the progestins is critical to successful treatment.
  • However, there are few studies detailing the histopathologic changes associated with progestin therapy.
  • The pretreatment and posttreatment endometrial samples were evaluated for response to treatment and for the histologic features of gland-to-stroma ratio, architectural abnormalities [back-to-back glands and confluency (cribriform and/or papillary patterns)], glandular cellularity, mitotic activity, cytologic atypia, and cytoplasmic changes.
  • Histologic changes seen in progestin-treated endometria included a decreased gland-to-stroma ratio, decreased glandular cellularity, decreased to absent mitotic activity, loss of cytologic atypia, and a variety of cytoplasmic changes including mucinous, secretory, squamous, and eosinophilic metaplasia.
  • Architectural changes tended to resolve later in the course of treatment.
  • Three instances of disease progression occurred, presumably only after discontinuing progestin treatment.
  • Only persistent architectural abnormalities and/or cytologic atypia in the 7 to 9-month biopsies were predictive of treatment failure, with a trend for cytologic atypia to be the most powerful predictor.
  • These findings indicate that progestin therapy should be continued for no less than 6 months to accurately assess treatment response.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Progestins / therapeutic use
  • [MeSH-minor] Adult. Cell Nucleus / drug effects. Disease Progression. Endometrium / drug effects. Endometrium / pathology. Female. Humans. Middle Aged. Retrospective Studies

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592264.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Progestins
  •  go-up   go-down






Advertisement